source
- Takeda braces for $2.5 billion charge after losing Amitiza antitrust case, plans appealTakeda Pharmaceutical has revised its financial outlook to include a potential $2.5 billion charge stemming from a recent antitrust lawsuit loss involving its laxative product Amitiza. The US Dist…
- Novo Nordisk aims to bring triple-G obesity injection to market by 2030Novo Nordisk said it plans to launch a triple‑G obesity injection by 2030. The drug would combine agonist activity at the GLP‑1, GIP and glucagon receptors, a class that researchers believe could b…